Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: A Korean Gynecologic Oncology Group study

Taek Sang Lee, Soon Beom Kang, Young Tak Kim, Byung Joo Park, Yong Man Kim, Jong Min Lee, Seok Mo Kim, Young Tae Kim, Jae Hoon Kim, Kyung Tai Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and toxicity of concurrent chemoradiation with paclitaxel and carboplatin in patients with high-risk cervical cancer. Methods and Materials: Patients after radical hysterectomy for cervical cancer, with at least 1 high-risk characteristic, were administered paclitaxel 135 mg/m2, carboplatin area under the curve = 5 every 3 weeks for 3 cycles concomitant with radiation therapy as adjuvant treatment. Results: This prospective study enrolled 71 consecutive patients. Sixty-six patients (93%) completed the planned treatment. The majority of grade 3/4 neutropenia or nonhematologic toxicities were usually self-limited. Diarrhea grades 3/4 were observed in 4 patients (5.6%). One patient developed anaphylactic shock after infusion of paclitaxel. With a median follow-up of 57 months, recurrences occurred in 16 patients. Multivariable analysis indicated that common iliac lymph node involvement is an independent risk factor for disease recurrence (odds ratio 13.48; 95% confidence interval 2.93-62.03). In the intent-to-treat population (n=71), the estimated 5-year disease-free survival and overall survival rates were 77.3% and 80.3% respectively. In the per-protocol population (n=62), disease-free survival was 78.9% and overall survival was 83.9%. Conclusions: Concurrent chemoradiation with paclitaxel/carboplatin is well tolerated and seems to be effective for patients who undergo radical hysterectomy. Therefore, a prospective, randomized controlled study should be designed to evaluate efficacy of this approach for patients with high-risk cervical cancer.

Original languageEnglish
Pages (from-to)304-310
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume86
Issue number2
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

Carboplatin
Paclitaxel
Hysterectomy
Uterine Cervical Neoplasms
cancer
toxicity
Disease-Free Survival
grade
Recurrence
lymphatic system
Anaphylaxis
Neutropenia
Population
Area Under Curve
confidence
radiation therapy
Diarrhea
Radiotherapy
Survival Rate
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Lee, Taek Sang ; Kang, Soon Beom ; Kim, Young Tak ; Park, Byung Joo ; Kim, Yong Man ; Lee, Jong Min ; Kim, Seok Mo ; Kim, Young Tae ; Kim, Jae Hoon ; Kim, Kyung Tai. / Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy : A Korean Gynecologic Oncology Group study. In: International Journal of Radiation Oncology Biology Physics. 2013 ; Vol. 86, No. 2. pp. 304-310.
@article{3b82d8b314da45cd91fef2e8e0799c7e,
title = "Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: A Korean Gynecologic Oncology Group study",
abstract = "Purpose: To evaluate the efficacy and toxicity of concurrent chemoradiation with paclitaxel and carboplatin in patients with high-risk cervical cancer. Methods and Materials: Patients after radical hysterectomy for cervical cancer, with at least 1 high-risk characteristic, were administered paclitaxel 135 mg/m2, carboplatin area under the curve = 5 every 3 weeks for 3 cycles concomitant with radiation therapy as adjuvant treatment. Results: This prospective study enrolled 71 consecutive patients. Sixty-six patients (93{\%}) completed the planned treatment. The majority of grade 3/4 neutropenia or nonhematologic toxicities were usually self-limited. Diarrhea grades 3/4 were observed in 4 patients (5.6{\%}). One patient developed anaphylactic shock after infusion of paclitaxel. With a median follow-up of 57 months, recurrences occurred in 16 patients. Multivariable analysis indicated that common iliac lymph node involvement is an independent risk factor for disease recurrence (odds ratio 13.48; 95{\%} confidence interval 2.93-62.03). In the intent-to-treat population (n=71), the estimated 5-year disease-free survival and overall survival rates were 77.3{\%} and 80.3{\%} respectively. In the per-protocol population (n=62), disease-free survival was 78.9{\%} and overall survival was 83.9{\%}. Conclusions: Concurrent chemoradiation with paclitaxel/carboplatin is well tolerated and seems to be effective for patients who undergo radical hysterectomy. Therefore, a prospective, randomized controlled study should be designed to evaluate efficacy of this approach for patients with high-risk cervical cancer.",
author = "Lee, {Taek Sang} and Kang, {Soon Beom} and Kim, {Young Tak} and Park, {Byung Joo} and Kim, {Yong Man} and Lee, {Jong Min} and Kim, {Seok Mo} and Kim, {Young Tae} and Kim, {Jae Hoon} and Kim, {Kyung Tai}",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.ijrobp.2013.01.035",
language = "English",
volume = "86",
pages = "304--310",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy : A Korean Gynecologic Oncology Group study. / Lee, Taek Sang; Kang, Soon Beom; Kim, Young Tak; Park, Byung Joo; Kim, Yong Man; Lee, Jong Min; Kim, Seok Mo; Kim, Young Tae; Kim, Jae Hoon; Kim, Kyung Tai.

In: International Journal of Radiation Oncology Biology Physics, Vol. 86, No. 2, 01.06.2013, p. 304-310.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy

T2 - A Korean Gynecologic Oncology Group study

AU - Lee, Taek Sang

AU - Kang, Soon Beom

AU - Kim, Young Tak

AU - Park, Byung Joo

AU - Kim, Yong Man

AU - Lee, Jong Min

AU - Kim, Seok Mo

AU - Kim, Young Tae

AU - Kim, Jae Hoon

AU - Kim, Kyung Tai

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Purpose: To evaluate the efficacy and toxicity of concurrent chemoradiation with paclitaxel and carboplatin in patients with high-risk cervical cancer. Methods and Materials: Patients after radical hysterectomy for cervical cancer, with at least 1 high-risk characteristic, were administered paclitaxel 135 mg/m2, carboplatin area under the curve = 5 every 3 weeks for 3 cycles concomitant with radiation therapy as adjuvant treatment. Results: This prospective study enrolled 71 consecutive patients. Sixty-six patients (93%) completed the planned treatment. The majority of grade 3/4 neutropenia or nonhematologic toxicities were usually self-limited. Diarrhea grades 3/4 were observed in 4 patients (5.6%). One patient developed anaphylactic shock after infusion of paclitaxel. With a median follow-up of 57 months, recurrences occurred in 16 patients. Multivariable analysis indicated that common iliac lymph node involvement is an independent risk factor for disease recurrence (odds ratio 13.48; 95% confidence interval 2.93-62.03). In the intent-to-treat population (n=71), the estimated 5-year disease-free survival and overall survival rates were 77.3% and 80.3% respectively. In the per-protocol population (n=62), disease-free survival was 78.9% and overall survival was 83.9%. Conclusions: Concurrent chemoradiation with paclitaxel/carboplatin is well tolerated and seems to be effective for patients who undergo radical hysterectomy. Therefore, a prospective, randomized controlled study should be designed to evaluate efficacy of this approach for patients with high-risk cervical cancer.

AB - Purpose: To evaluate the efficacy and toxicity of concurrent chemoradiation with paclitaxel and carboplatin in patients with high-risk cervical cancer. Methods and Materials: Patients after radical hysterectomy for cervical cancer, with at least 1 high-risk characteristic, were administered paclitaxel 135 mg/m2, carboplatin area under the curve = 5 every 3 weeks for 3 cycles concomitant with radiation therapy as adjuvant treatment. Results: This prospective study enrolled 71 consecutive patients. Sixty-six patients (93%) completed the planned treatment. The majority of grade 3/4 neutropenia or nonhematologic toxicities were usually self-limited. Diarrhea grades 3/4 were observed in 4 patients (5.6%). One patient developed anaphylactic shock after infusion of paclitaxel. With a median follow-up of 57 months, recurrences occurred in 16 patients. Multivariable analysis indicated that common iliac lymph node involvement is an independent risk factor for disease recurrence (odds ratio 13.48; 95% confidence interval 2.93-62.03). In the intent-to-treat population (n=71), the estimated 5-year disease-free survival and overall survival rates were 77.3% and 80.3% respectively. In the per-protocol population (n=62), disease-free survival was 78.9% and overall survival was 83.9%. Conclusions: Concurrent chemoradiation with paclitaxel/carboplatin is well tolerated and seems to be effective for patients who undergo radical hysterectomy. Therefore, a prospective, randomized controlled study should be designed to evaluate efficacy of this approach for patients with high-risk cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=84877283986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877283986&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2013.01.035

DO - 10.1016/j.ijrobp.2013.01.035

M3 - Article

C2 - 23642625

AN - SCOPUS:84877283986

VL - 86

SP - 304

EP - 310

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -